Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential Melphalan/HDS and Sorafenib in Unresectable HCC
NCT02406508Phase 2Withdrawn
- Sponsor
- Delcath Systems
- Start
- Oct 2014
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of melphalan in hepatocellular carcinoma (HCC), sponsored by Delcath Systems. Planned start Oct 2014; status: withdrawn.
02
Drugs
melphalan
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02406508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02406508.